PARADIGM SHIFTING DRUGS

FOR LIFE-THREATENING
BLOOD DISEASES

PARADIGM SHIFTING DRUGS

FOR BLOOD DISEASES

FIRST-IN-CLASS

SAFE BIOLOGIC DRUGS

Aronora is committed to developing and
commercializing safe, first-in-class medicines
for blood diseases with significant unmet
medical need.

MORE ABOUT US

FIRST-IN-CLASS

SAFE BIOLOGIC DRUGS

Aronora is committed to developing and commercializing safe, first-in-class medicines for blood diseases with significant unmet medical need.

MORE ABOUT US

OUR

PIPELINE

Our pipeline of innovative product candidates target disease modifying pathways with unique mechanisms of action.

Program Target/Moa Discovery Ind-Enabling Studies Phase 1 Phase 2 Phase 3
AB002

The company’s lead product candidate, AB002 (E-WE thrombin), is a first-in-class protein C activator enzyme. AB002 has been designed to act in part by increasing the surface concentration of the anticoagulant, profibrinolytic, and cytoprotective enzyme, endogenous activated protein C (APC), at the site of developing blood clots via targeted cellular delivery. This unique mechanism of action allows AB002 to target cell-rich pathological blood clots (thrombi) without disabling vital hemostasis. AB002 is currently in the phase 2 clinical trial stage and has received FDA Fast Track designation. It is being developed for heparin intolerant end-stage renal disease patients on chronic hemodialysis who require safe and brief (3-4 hour) anticoagulation to reduce hemodialyzer clotting and associated blood loss during the procedure. There is no drug on the market specifically approved by the FDA for this patient population. Other target indications include heart attack, acute ischemic stroke, pulmonary embolism, and peri-interventional thromboprophylaxis.

RIGHTS

CLINICAL TRIALS
PUBLICATIONS
Protein C  
Phase 2
100%
AB023

AB023 (Gruticibart) is a recombinant factor XI (FXI) antibody that specifically inhibits contact activation of blood. AB023 is entirely unique in the growing armamentarium of FXI targeting drugs under development since it specifically inhibits FXI activation by factor XII (FXII) without inhibiting FXI feedback activation by thrombin. Since FXII deficiency in humans does not result in any known bleeding side-effects, as opposed to FXI deficiency (also known as hemophilia C), AB023 could be an exceptionally safe antithrombotic agent. As such, AB023 represents a fundamentally novel antithrombotic concept. AB023 is currently in the phase 2 clinical trial stage. It is being developed to prevent various thrombotic complications associated with chronic hemodialysis, as well as to limit blood clot formation on catheters and other intravascular, intracardiac or extracorporeal medical devices.

RIGHTS

CLINICAL TRIALS
PUBLICATIONS
Factor XI  
Phase 2
100%
LEARN MORE

OUR

PIPELINE

Our pipeline of innovative product candidates target disease modifying pathways with unique mechanisms of action.

Discovery
Ind-Enabling Studies
Phase 1
Phase 2
Phase 3
AB002
(E-WE thrombin)

The company’s lead product candidate, AB002 (E-WE thrombin), is a first-in-class protein C activator enzyme. AB002 has been designed to act in part by increasing the surface concentration of the anticoagulant, profibrinolytic, and cytoprotective enzyme, endogenous activated protein C (APC), at the site of developing blood clots via targeted cellular delivery. This unique mechanism of action allows AB002 to target cell-rich pathological blood clots (thrombi) without disabling vital hemostasis. AB002 is currently in the phase 2 clinical trial stage and has received FDA Fast Track designation. It is being developed for heparin intolerant end-stage renal disease patients on chronic hemodialysis who require safe and brief (3-4 hour) anticoagulation to reduce hemodialyzer clotting and associated blood loss during the procedure. There is no drug on the market specifically approved by the FDA for this patient population. Other target indications include heart attack, acute ischemic stroke, pulmonary embolism, and peri-interventional thromboprophylaxis.

RIGHTS

CLINICAL TRIALS
PUBLICATIONS
 
Phase 2
100%
AB023
(Gruticibart)

AB023 (Gruticibart) is a recombinant factor XI (FXI) antibody that specifically inhibits contact activation of blood. AB023 is entirely unique in the growing armamentarium of FXI targeting drugs under development since it specifically inhibits FXI activation by factor XII (FXII) without inhibiting FXI feedback activation by thrombin. Since FXII deficiency in humans does not result in any known bleeding side-effects, as opposed to FXI deficiency (also known as hemophilia C), AB023 could be an exceptionally safe antithrombotic agent. As such, AB023 represents a fundamentally novel antithrombotic concept. AB023 is currently in the phase 2 clinical trial stage. It is being developed to prevent various thrombotic complications associated with chronic hemodialysis, as well as to limit blood clot formation on catheters and other intravascular, intracardiac or extracorporeal medical devices.

RIGHTS

CLINICAL TRIALS
PUBLICATIONS
 
Phase 2
100%
LEARN MORE

NEWS &

MEDIA

October 12, 2023

December 8, 2022

JULY 19, 2021

March 2, 2021

January 8, 2021

SEE MORE NEWS